Markets and Indications
Ischemia: NeurOp scientists believe that maximum neuroprotection may be achieved by administering drug prior to an ischemic insult. The initial indications the Company will pursue involve predictable ischemic events that cause cognitive and neurological deficits. These include vascular surgical procedures and subarachnoid hemorrhage (SAH). The cumulative market for these indications exceeds $2.5B/year.
Predictable Ischemic Events: SAH and Vascular Surgery
 |
Indications & Patient No. CABG: 700,000 CEA: 350,000 Valve Repair: 200,000 SAH: 80,000 Ped Cardiac: 25,000 Total: 1.35 mil patients. Market ~ $2.7B |
Aside from thrombolytic agents such as tPA, there are no approved drugs for stroke. The anticipated favorable safety profile of NeurOp compounds would enable for the first time, prophylactic administration of an effective neuroprotectant to those at risk for stroke. This is an extremely large patient population which includes stroke survivors, patients who have experienced a transient ischemic attack (TIA) or silent stroke, patients with atrial fibrillation and many others. By 2010 this market could easily top $15B/year.
Neuropathic Pain: The worldwide neuropathic pain therapeutics market is projected to exceed $5B/year by 2009. Conditions associated with neuropathic pain include:
|
|
Markets for all Indications:
 |
Ischemia: $16B Pain: $5B Neurodegenerative Disease: $3B |
Home - Our Team - Technology - Markets and Indications - Funding Strategy - Press Releases - Contact Us